WHAT'S REPORTED
- ▸Phase 3 clinical trial published in JAMA found trastuzumab rezetecan linked to 73% lower risk of cancer progression or death versus chemotherapy. — Fox News Health
THE BRIEF
A phase 3 trial published in JAMA found trastuzumab rezetecan cut progression or death risk by 73% in advanced breast cancer.
WHAT'S REPORTED
A federal judge blocked the Trump administration's Medicaid work requirement rule requiring proof of medical frailty.
WHAT'S REPORTED
Bodum recalled nearly 6 million French press coffee makers over burn risk from breaking glass carafes.
WHAT'S REPORTED
Eli Lilly's retatrutide reduced breathing interruptions and drove weight loss in sleep apnea patients.
WHAT'S REPORTED
A Washington Post investigation found fresh produce imported into the US is rarely inspected.
WHAT'S REPORTED